Safety and potential heart-healthy benefits of SGLT2 inhibitors for kidney transplant patients with diabetes
Official title: An Exploratory Investigation of the Safety of Empagliflozin in Kidney Transplant Recipients (SEKTR)
Funded at Omaha VA Medical Center · NIH-11252581 · Data updated 2026-11-12
A multi-site study will gently test whether SGLT2 inhibitors can be safely used in kidney transplant recipients who have type 2 diabetes, to see if it helps both the graft and heart health.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Omaha VA Medical Center NIH-funded |
| Lab location | 1 site (Omaha, United States) |
| Project start | January 1, 2024 |
| Project end | March 31, 2029 |
| Funding year | 2026 |
| NIH project number | 5I01CX002666-03 |
| Project ID | NIH-11252581 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults who have a kidney transplant, have type 2 diabetes, and are eligible for SGLT2 inhibitors.
✕Less likely to help
Patients with active infections or contraindications to SGLT2 inhibitors or those at high risk for graft-related complications may not benefit.
What this research studies
This project focuses on veterans with kidney transplants and type 2 diabetes to see if a class of diabetes medicines called SGLT2 inhibitors can be used safely. It will monitor for infection risk, effects on the transplanted kidney, and any changes in heart-related outcomes. The study will be conducted at four VA centers, collecting information to understand real-world effects on graft function and cardiovascular health. If the results look favorable, it could inform future care options for transplant recipients with diabetes.
Why it matters
Potential benefit: If successful, patients could have better heart and kidney outcomes and more options for managing diabetes after transplantation.
How similar studies have gone: Previous CKD studies show kidney and heart benefits with SGLT2 inhibitors, but KTRs have been excluded; this study tests applicability to transplant recipients.
Where this research is happening
-
Omaha VA Medical Center
Omaha, United States Active
Researchers
- Principal investigator: Mannon, Roslyn B — Omaha VA Medical Center
- Study coordinator: Mannon, Roslyn B
Related research
Other NIH-funded projects on the same topics.
-
Microbial clues to diagnose and predict infections in kidney transplant patients
A patient-focused project will look for microbial biomarkers in stool, blood, and urine to help doctors predict and diagnose infections in people who have had a kidney transplant.
-
Immunological mechanisms behind treatment-resistant kidney transplant rejection
This grant explores why certain kidney transplant rejections don’t respond to standard treatments and what immune cells in the graft are driving that resistance.
-
Complement-Bound Exosomes and Kidney Transplant Immunity
This project studies how kidney transplant injury and rejection happen after surgery and whether blocking certain immune pathways during organ preservation could improve transplant outcomes.
-
Blood vessel signals predicting heart problems after kidney transplant
This project studies blood markers and tissue patterns after kidney transplants to identify which patients are at highest risk of cardiovascular problems.
-
Understanding how BK virus links infection to kidney transplant rejection
This project looks at how BK polyomavirus reactivation affects kidney transplant patients and aims to use pre-transplant T cell information to tailor immunosuppression and monitoring.
-
Characterization of a LILRB3 SNP cluster and its link to kidney transplant outcomes
A study in kidney transplant recipients looks at genetic factors that may be tied to higher risk of graft failure.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.